                                  DC REGULATIONS

PROVIDER PARTICIPATION (§ 29-2701)

2701.1. A provider of pharmacy services shall be a licensed pharmacy.  To
   participate in the District of Columbia’s Medicaid Program, the provider
   shall:
   
   
   
   
   
   
   
   Fully comply with any applicable District, state and federal laws or
   regulations governing the provision and reimbursement of pharmacy services;
   and
   
   
   
   (b) 	Complete and sign the Medicaid Provider Agreement.

   2701.2. As a condition of participation, the provider shall be required to
   comply with the following requirements:
   
   
   
   
   
   
   
   Perform prospective drug utilization review before dispensing each
   prescription.  This shall include screenings for, but not limited to, the
   following:
   
   
   
   
   
   
   
   Therapeutic duplication;
   
   
   
   
   
   
   
   Drug-disease contraindications;
   
   
   
   
   
   
   
   Drug interactions;
   
   
   
   
   
   
   
   Incorrect dosage indication, or duration;
   
   
   
   (5)  	Drug allergies; and
   
   
   
   
   
   
   
   Abuse or misuse;
   
   
   
   
   
   
   
   Provide patient counseling on all matters which, in the provider’s
   professional judgment, shall be deemed significant, including:
   
   
   
   
   
   
   
   Name and/or description of the medication;
   
   
   
   
   
   
   
   Route, dosage form, and duration of therapy;
   
   
   
   
   
   
   
   Directions for use;
   
   
   
   
   
   
   
   Common side effects;
   
   
   
   
   
   
   
   Potential adverse reactions, contraindications;
   
   
   
   
   
   
   
   Storage; and
   
   
   
   
   
   
   
   Refill information; and
   
   
   
   
   
   
   
   Obtain, record, and maintain patient profiles including the following:
   
   
   
   
   
   
   
   Name, address, phone number, age and gender;
   
   
   
   
   
   
   
   Individual history (i.e., diseases, allergies, drug reactions);
   
   
   
   
   
   
   
   Comprehensive listing of medications; and
   
   
   
   
   
   
   
   Relevant comments.
   
   
   
   		SOURCE: Notice of Final Rulemaking published at 59 DCR 2298, 2300 (March 23,
   2012).
